Abstracts tagged "clinical trials and osteoporosis"

Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
H Ishibashi¹, DB Crittenden², A Miyauchi³, C Libanati⁴, J Maddox², L Chen² and A Grauer², ¹Ina Hospital, Saitama, Japan, ²Amgen Inc., Thousand Oaks, CA, ³Miyauchi Medical Center, Osaka, Japan, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
Abstract Number: 863 • 2013 ACR/ARHP Annual Meeting
Romosozumab Administration Is Associated With Significant Improvements In Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide
H K Genant¹, S Boonen², M A Bolognese³, C Mautalen⁴, J P Brown⁵, C Recknor⁶, S Goemaere⁷, K Engelke⁸, Y-C Yang⁹, M Austin⁹, A Grauer⁹ and C Libanati⁹, ¹UCSF & Synarc Inc., San Francisco, CA, ²Leuven University Division of Geriatric Medicine, Leuven, Belgium, ³The Bethesda Health Research Center, Bethesda, MD, ⁴Centro de Osteopatias Medicas, Buenos Aires, Argentina, ⁵CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Synarc Germany, Hamburg, Germany, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody to sclerostin stimulates bone formation and decreases bone resorption. In a phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].